PROSPECTS FOR THE USE OF MESENCHYMAL STEM CELLS IN THE TREATMENT OF CONGENITAL EPIDERMOLYSIS BULLOSA
Main Article Content
Authors
M.R. Rysuly
RSE “Kazakh Scientific Center of Dermatology and Infectious Diseases”, Almaty, Kazakhstan
V.B. Ogay
LLP “National Center of Biotechnology”, Astana, Kazakhstan
S.A. Ospanova
RSE “Kazakh Scientific Center of Dermatology and Infectious Diseases”, Almaty, Kazakhstan
A.K. Nurkina
LLP “National Center of Biotechnology”, Astana, Kazakhstan
A.A. Taubaeva
RSE “Kazakh Scientific Center of Dermatology and Infectious Diseases”, Almaty, Kazakhstan
E.N. Islamov
PSE "Dermatovenerologic dispensary" of the Almaty Health Center, Almaty, Kazakhstan
A.S. Idrisova
RSE “Kazakh Scientific Center of Dermatology and Infectious Diseases”, Almaty, Kazakhstan
V.V. Pavlova
PSE "Dermatovenerologic dispensary" of the Almaty Health Center, Almaty, Kazakhstan
Abstract
Epidermolysis bullosa (EB) is a hereditary orphan pathology caused by mutations in genes encoding structural cellular proteins necessary for the integrity of the skin and mucous membranes. As a result of minor mechanical stress, blisters with serous and/or hemorrhagic contents, long-term non-healing wounds and scars form on the skin. Such injuries have a high risk of infectious complications and often lead to disability of the patient. Current treatment methods are primarily palliative in nature and aimed at preventing complications, which emphasizes the relevance in new therapeutic strategies.
Mesenchymal stem cells (MSCs) offer a promising therapeutic approach. MSCs are known for their multipotency, immunomodulatory properties, and ability to promote tissue repair, a potential treatment for epidermolysis bullosa. This literature review evaluates the therapeutic potential of MSCs in the treatment of VEB, highlighting key findings from recent studies.
Keywords
epidermolysis bullosa congenital, complications, mesenchymal stem cells, cell therapy, mutations, genome editing
Article Details
References
Bergson S., Daniely D., Bomze D., Mohamad J., Malovitski K., Meijers O., Briskin V., Bihari O., Malchin N., Israeli S., Mashiah J., Falik-Zaccai T., Avitan-Hersh E., Eskin-Schwartz M., Allon-Shalev S., Sarig O., Sprecher E., Samuelov L. Clinical and molecular features in a cohort of Middle Eastern patients with epidermolysis bullosa // Pediatr Dermatol. – 2023. – Vol. 40. – №6. – P. 1021-1027. DOI 10.1111/pde.15440.
Fine J.-D. Epidemiology of Inherited Epidermolysis Bullosa Based on Incidence and Prevalence Estimates From the National Epidermolysis Bullosa Registry // JAMA Dermatol. – 2016. – Vol. 152. – № 11. – P. 1231-1238. DOI 10.1001/jamadermatol.2016.2473.
Bruckner A.L., Losow M., Wisk J., Patel N., Reha A., Lagast H., Gault J., Gershkowitz J., Kopelan B., Hund M., Murrell D.F. The Challenges of Living with and Managing Epidermolysis Bullosa: Insights from Patients and Caregivers // Orphanet J. Rare Dis. – 2020. – Vol. 15. – № 1. – DOI 10.1186/s13023-019-1279-y. PMID: 31900176.
Han Y., Li X., Zhang Y., Han Y., Chang F., Ding J. Mesenchymal Stem Cells for Regenerative Medicine // Cells. – 2019. – Vol. 8. – № 8. – P. 886. DOI 10.3390/cells8080886. PMID: 31412678; PMCID: PMC6721852.
Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., Moorman M.A., Simonetti D.W., Craig S., Marshak D.R. Multilineage potential of adult human mesenchymal stem cells // Science. – 1999. – Vol. 284. – № 5411. – P. 143-147. DOI 10.1126/science.284.5411.143. PMID: 10102814.
Zuk P.A., Zhu M., Mizuno H., Huang J., Futrell J.W., Katz A.J., Benhaim P., Lorenz H.P., Hedrick M.H. Multilineage cells from human adipose tissue: implications for cell-based therapies // Tissue Eng. – 2001. – Vol. 7. – № 2. – P. 211-228. DOI 10.1089/107632701300062859. PMID: 11304456.
Greish S., Abogresha N., Abdel-Hady Z., Zakaria E., Ghaly M., Hefny M. Human umbilical cord mesenchymal stem cells as treatment of adjuvant rheumatoid arthritis in a rat model // World J. Stem Cells. – 2012. – Vol. 4. – № 10. – P. 101-109. DOI 10.4252/wjsc.v4.i10.101. PMID: 23189211; PMCID: PMC3506964.
De Miguel M.P., Fuentes-Julián S., Blázquez-Martínez A., Pascual C.Y., Aller M.A., Arias J., Arnalich-Montiel F. Immunosuppressive properties of mesenchymal stem cells: advances and applications // Curr. Mol. Med. – 2012. – Vol. 12. – № 5. – P. 574-591. DOI 10.2174/156652412800619950. PMID: 22515979.
Lee S.E., Lee S.-J., Kim S.-E., Kim K., Cho B., Roh K., Kim S.-C. Intravenous allogeneic umbilical cord blood-derived mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa patients // JCI Insight. – 2021. – Vol. 6. – № 2. – P. e143606. DOI 10.1172/jci.insight.143606. PMID: 33491668; PMCID: PMC7934866.
Kiritsi D., Dieter K., Niebergall-Roth E., Fluhr S., Daniele C., Esterlechner J., Sadeghi S., Ballikaya S., Erdinger L., Schauer F., Gewert S., Laimer M., Bauer J.W., Hovnanian A., Zambruno G., El Hachem M., Bourrat E., Papanikolaou M., Petrof G., Kitzmüller S., Ebens C.L., Frank M.H., Frank N.Y., Ganss C., Martinez A.E., McGrath J.A., Tolar J., Kluth M.A. Clinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa // JCI Insight. – 2021. – Vol. 6. – № 22. – P. e151922. DOI 10.1172/jci.insight.151922. PMID: 34665781; PMCID: PMC8663784.
McBride J.D., Rodriguez-Menocal L., Candanedo A., Guzman W., Garcia-Contreras M., Badiavas E.V. Dual mechanism of type VII collagen transfer by bone marrow mesenchymal stem cell extracellular vesicles to recessive dystrophic epidermolysis bullosa fibroblasts // Biochimie. – 2018. – Vol. 155. – P. 50-58. DOI 10.1016/j.biochi.2018.04.007. PMID: 29653141.
Webber B.R., Osborn M.J., McElroy A.N., Twaroski K., Lonetree C.L., DeFeo A.P., Xia L., Eide C., Lees C.J., McElmurry R.T., Riddle M.J., Kim C.J., Patel D.D., Blazar B.R., Tolar J. CRISPR/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa // NPJ Regen. Med. – 2016. – Vol. 1. – P. 16014. DOI 10.1038/npjregenmed.2016.14. PMID: 28250968; PMCID: PMC5328670.
Bonafont J., Mencía A., Chacón-Solano E., Srifa W., Vaidyanathan S., Romano R., Garcia M., Hervás-Salcedo R., Ugalde L., Duarte B., Porteus M.H., Del Rio M., Larcher F., Murillas R. Correction of recessive dystrophic epidermolysis bullosa by homology-directed repair-mediated genome editing // Mol. Ther. – 2021. – Vol. 29. – № 6. – P. 2008-2018. DOI 10.1016/j.ymthe.2021.02.019. PMID: 33609734; PMCID: PMC8178438.
Schosserer M., Reynoso R., Wally V., Jug B., Kantner V., Weilner S., Buric I., Grillari J., Bauer J.W., Grillari-Voglauer R. Urine is a novel source of autologous mesenchymal stem cells for patients with epidermolysis bullosa // BMC Res Notes. – 2015. – Vol. 8. – P. 767. DOI 10.1186/s13104-015-1686-7. PMID: 26654529; PMCID: PMC4676112.
Kikuchi Y., Tamakoshi T., Ishida R., Kobayashi R., Mori S., Ishida-Yamamoto A., Fujimoto M., Kaneda Y., Tamai K. Gene-Modified Blister Fluid-Derived Mesenchymal Stromal Cells for Treating Recessive Dystrophic Epidermolysis Bullosa // J. Invest Dermatol. – 2023. – Vol. 143. – № 12. – P. 2447-2455.e8. DOI 10.1016/j.jid.2023.05.021. PMID: 37302620.
Riedl J., Pickett-Leonard M., Eide C., Kluth M.A., Ganss C., Frank N.Y., Frank M.H., Ebens C.L., Tolar J. ABCB5+ dermal mesenchymal stromal cells with favorable skin homing and local immunomodulation for recessive dystrophic epidermolysis bullosa treatment // Stem Cells. – 2021. – Vol. 39. – № 7. – P. 897-903. DOI 10.1002/stem.3356. PMID: 33609408; PMCID: PMC8278965.
Petrova A., Georgiadis C., Fleck R.A., Allison L., McGrath J.A., Dazzi F., Di W.L., Qasim W. Human Mesenchymal Stromal Cells Engineered to Express Collagen VII Can Restore Anchoring Fibrils in Recessive Dystrophic Epidermolysis Bullosa Skin Graft Chimeras // J. Invest Dermatol. – 2020. – Vol. 140. – № 1. – P. 121-131.e6. DOI 10.1016/j.jid.2019.05.031. PMID: 31326396.
Perdoni C., McGrath J.A., Tolar J. Preconditioning of mesenchymal stem cells for improved transplantation efficacy in recessive dystrophic epidermolysis bullosa // Stem Cell Res Ther. – 2014. – Vol. 5. – № 6. – P. 121. DOI 10.1186/scrt511. PMID: 25376815; PMCID: PMC4446116.
Nevala-Plagemann C., Lee C., Tolar J. Placenta-based therapies for the treatment of epidermolysis bullosa // Cytotherapy. – 2015. – Vol. 17. – № 6. – P. 786-795. DOI 10.1016/j.jcyt.2015.03.006. PMID: 25795271; PMCID: PMC4424102.
Niebergall-Roth E., Dieter K., Daniele C., Fluhr S., Khokhrina M., Silva I., Ganss C., Frank M.H., Kluth M.A. Kinetics of Wound Development and Healing Suggests a Skin-Stabilizing Effect of Allogeneic ABCB5+ Mesenchymal Stromal Cell Treatment in Recessive Dystrophic Epidermolysis Bullosa // Cells. – 2023. – Vol. 12. – № 11. – P. 1468. DOI 10.3390/cells12111468. PMID: 37296590; PMCID: PMC10252830.
Petrof G., Lwin S.M., Martinez-Queipo M., Abdul-Wahab A., Tso S., Mellerio J.E., Slaper-Cortenbach I., Boelens J.J., Tolar J., Veys P., Ofuya M., Peacock J.L., Martinez A.E., McGrath J.A. Potential of Systemic Allogeneic Mesenchymal Stromal Cell Therapy for Children with Recessive Dystrophic Epidermolysis Bullosa // J Invest Dermatol. – 2015. – Vol. 135. – № 9. – P. 2319-2321. DOI 10.1038/jid.2015.158. PMID: 25905587; PMCID: PMC5696540.
Schatton T., Yang J., Kleffel S., Uehara M., Barthel S.R., Schlapbach C., Zhan Q., Dudeney S., Mueller H., Lee N., de Vries J.C., Meier B., Vander Beken S., Kluth M.A., Ganss C., Sharpe A.H., Waaga-Gasser A.M., Sayegh M.H., Abdi R., Scharffetter-Kochanek K., Murphy G.F., Kupper T.S., Frank N.Y., Frank M.H. ABCB5 Identifies Immunoregulatory Dermal Cells // Cell Rep. – 2015. – Vol. 12. – № 10. – P. 1564-1574. DOI 10.1016/j.celrep.2015.08.010. PMID: 26321644; PMCID: PMC4565759.
Beken S.V., de Vries J.C., Meier-Schiesser B., Meyer P., Jiang D., Sindrilaru A., Ferreira F.F., Hainzl A., Schatz S., Muschhammer J., et al. Newly Defined ATP-Binding Cassette Subfamily B Member 5 Positive Dermal Mesenchymal Stem Cells Promote Healing of Chronic Iron-Overload Wounds via Secretion of Interleukin-1 Receptor Antagonist // Stem Cells. – 2019. – Vol. 37. – P. 1057-1074. DOI 10.1002/stem.3356.
Kiritsi D., Dieter K., Niebergall-Roth E., Fluhr S., Daniele C., Esterlechner J., Sadeghi S., Ballikaya S., Erdinger L., Schauer F., Gewert S., Laimer M., Bauer J.W., Hovnanian A., Zambruno G., El Hachem M., Bourrat E., Papanikolaou M., Petrof G., Kitzmüller S., Ebens C.L., Frank M.H., Frank N.Y., Ganss C., Martinez A.E., McGrath J.A., Tolar J., Kluth M.A. Clinical trial of ABCB5+ mesenchymal stem cells for recessive dystrophic epidermolysis bullosa // JCI Insight. – 2021. – Vol. 6. – № 22. – P. e151922. DOI 10.1172/jci.insight.151922. PMID: 34665781; PMCID: PMC8663784.
Jayarajan V., Kounatidou E., Qasim W., Di W.L. Ex vivo gene modification therapy for genetic skin diseases—recent advances in gene modification technologies and delivery // Exp Dermatol. – 2021. – Vol. 30. – № 7. – P. 887-896. DOI 10.1111/exd.14314. PMID: 33657662; PMCID: PMC8432139.
Dellambra E., Pellegrini G., Guerra L., Ferrari G., Zambruno G., Mavilio F., De Luca M. Toward epidermal stem cell-mediated ex vivo gene therapy of junctional epidermolysis bullosa // Hum Gene Ther. – 2000. – Vol. 11. – № 16. – P. 2283-2287. DOI 10.1089/104303400750035825. PMID: 11084687.
Rheinwald J.G., Green H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells // Cell. – 1975. – Vol. 6. – № 3. – P. 331-343. DOI 10.1016/s0092-8674(75)80001-8. PMID: 1052771.
Boyce S.T., Kagan R.J., Yakuboff K.P., Meyer N.A., Rieman M.T., Greenhalgh D.G., Warden G.D. Cultured Skin Substitutes Reduce Donor Skin Harvesting for Closure of Excised, Full-Thickness Burns // Ann Surg. – 2002. – Vol. 235. – № 2. – P. 269-279. DOI 10.1097/00000658-200202000-00016. PMID: 11807368; PMCID: PMC1422424.
Mavilio F., Pellegrini G., Ferrari S., Di Nunzio F., Di Iorio E., Recchia A., Maruggi G., Ferrari G., Provasi E., Bonini C., Capurro S., Conti A., Magnoni C., Giannetti A., De Luca M. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells // Nat Med. – 2006. – Vol. 12. – № 12. – P. 1397-1402. DOI 10.1038/nm1504. PMID: 17115047.
De Rosa L., Enzo E., Zardi G., Bodemer C., Magnoni C., Schneider H., De Luca M. Hologene 5: A Phase II/III Clinical Trial of Combined Cell and Gene Therapy of Junctional Epidermolysis Bullosa // Front Genet. – 2021. – Vol. 12. – P. 705019. DOI 10.3389/fgene.2021.705019. PMID: 34539738; PMCID: PMC8440932.
Bauer J.W., Koller J., Murauer E.M., De Rosa L., Enzo E., Carulli S., Bondanza S., Recchia A., Muss W., Diem A., Mayr E., Schlager P., Gratz I.K., Pellegrini G., De Luca M. Closure of a Large Chronic Wound through Transplantation of Gene-Corrected Epidermal Stem Cells // J Invest Dermatol. – 2017. – Vol. 137. – № 3. – P. 778-781. DOI 10.1016/j.jid.2016.10.038. PMID: 27840234.
Hirsch T., Rothoeft T., Teig N., Bauer J.W., Pellegrini G., De Rosa L., Scaglione D., Reichelt J., Klausegger A., Kneisz D., Romano O., Secone Seconetti A., Contin R., Enzo E., Jurman I., Carulli S., Jacobsen F., Luecke T., Lehnhardt M., Fischer M., Kueckelhaus M., Quaglino D., Morgante M., Bicciato S., Bondanza S., De Luca M. Regeneration of the entire human epidermis using transgenic stem cells // Nature. – 2017. – Vol. 551. – № 7680. – P. 327-332. DOI 10.1038/nature24487. PMID: 29144448; PMCID: PMC6283270.
Marinkovich M.P., Tang J.Y. Gene Therapy for Epidermolysis Bullosa // J Invest Dermatol. – 2019. – Vol. 139. – № 6. – P. 1221-1226. DOI 10.1016/j.jid.2018.11.036. PMID: 31068252.
Welponer T., Prodinger C., Pinon-Hofbauer J., Hintersteininger A., Breitenbach-Koller H., Bauer J.W., Laimer M. Clinical Perspectives of Gene-Targeted Therapies for Epidermolysis Bullosa // Dermatol Ther (Heidelb). – 2021. – Vol. 11. – № 4. – P. 1175-1197. DOI 10.1007/s13555-021-00561-5. PMID: 34110606; PMCID: PMC8322229.
Siprashvili Z., Nguyen N.T., Gorell E.S., Loutit K., Khuu P., Furukawa L.K., Lorenz H.P., Leung T.H., Keene D.R., Rieger K.E., Khavari P., Lane A.T., Tang J.Y., Marinkovich M.P. Safety and Wound Outcomes Following Genetically Corrected Autologous Epidermal Grafts in Patients With Recessive Dystrophic Epidermolysis Bullosa // JAMA. – 2016. – Vol. 316. – № 17. – P. 1808-1817. DOI 10.1001/jama.2016.15588. PMID: 27802546.
So J.Y., Nazaroff J., Iwummadu C.V., Harris N., Gorell E.S., Fulchand S., Bailey I., McCarthy D., Siprashvili Z., Marinkovich M.P., Tang J.Y., Chiou A.S. Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa // Orphanet J Rare Dis. – 2022. – Vol. 17. – № 1. – P. 377. DOI 10.1186/s13023-022-02546-9. PMID: 36253825; PMCID: PMC9574807.
Eichstadt S., Barriga M., Ponakala A., Teng C., Nguyen N.T., Siprashvili Z., Nazaroff J., Gorell E.S., Chiou A.S., Taylor L., Khuu P., Keene D.R., Rieger K., Khosla R.K., Furukawa L.K., Lorenz H.P., Marinkovich M.P., Tang J.Y. Phase 1/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa // JCI Insight. – 2019. – Vol. 4. – № 19. – P. e130554. DOI 10.1172/jci.insight.130554. PMID: 31578311; PMCID: PMC6795403.
Lwin S.M., Syed F., Di W.L., Kadiyirire T., Liu L., Guy A., Petrova A., Abdul-Wahab A., Reid F., Phillips R., Elstad M., Georgiadis C., Aristodemou S., Lovell P.A., McMillan J.R., Mee J., Miskinyte S., Titeux M., Ozoemena L., Pramanik R., Serrano S., Rowles R., Maurin C., Orrin E., Martinez-Queipo M., Rashidghamat E., Tziotzios C., Onoufriadis A., Chen M., Chan L., Farzaneh F., Del Rio M., Tolar J., Bauer J.W., Larcher F., Antoniou M.N., Hovnanian A., Thrasher A.J., Mellerio J.E., Qasim W., McGrath J.A. Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa // JCI Insight. – 2019. – Vol. 4. – № 11. – P. e126243. DOI 10.1172/jci.insight.126243. PMID: 31167965; PMCID: PMC6629162.
Marinkovich M., Lane A., Sridhar K., Keene D.R., Malyala A., Maslowski J. A phase 1/2 study of genetically-corrected, collagen VII expressing autologous human dermal fibroblasts injected into the skin of patients with recessive dystrophic epidermolysis bullosa (RDEB) // J Invest Dermatol. – 2018. – Vol. 138. – № 5. – P. S100. DOI 10.1016/j.jid.2018.03.599.
Mariath L.M., Santin J.T., Schuler-Faccini L., Kiszewski A.E. Inherited epidermolysis bullosa: update on the clinical and genetic aspects // An Bras Dermatol. – 2020. – Vol. 95. – № 5. – P. 551-569. DOI 10.1016/j.abd.2020.05.001. PMID: 32732072; PMCID: PMC7563003.
Maseda R., Martínez-Santamaría L., Sacedón R., Butta N., de Arriba M.D.C., García-Barcenilla S., García M., Illera N., Pérez-Conde I., Carretero M., Jiménez E., Melen G., Borobia A.M., Jiménez-Yuste V., Vicente Á., Del Río M., de Lucas R., Escámez M.J. Beneficial Effect of Systemic Allogeneic Adipose Derived Mesenchymal Cells on the Clinical, Inflammatory and Immunologic Status of a Patient With Recessive Dystrophic Epidermolysis Bullosa: A Case Report // Front Med (Lausanne). – 2020. – Vol. 7. – P. 576558. DOI 10.3389/fmed.2020.576558. PMID: 33324660; PMCID: PMC7726418.
Fujita Y., Nohara T., Takashima S., Natsuga K., Adachi M., Yoshida K., Shinkuma S., Takeichi T., Nakamura H., Wada O., Akiyama M., Ishiko A., Shimizu H. Intravenous allogeneic multilineage-differentiating stress-enduring cells in adults with dystrophic epidermolysis bullosa: a phase 1/2 open-label study // J Eur Acad Dermatol Venereol. – 2021. – Vol. 35. – № 8. – P. e528-e531. DOI 10.1111/jdv.17201. PMID: 33656198; PMCID: PMC8359848.
Niebergall-Roth E., Dieter K., Daniele C., Fluhr S., Khokhrina M., Silva I., Ganss C., Frank M.H., Kluth M.A. Kinetics of Wound Development and Healing Suggests a Skin-Stabilizing Effect of Allogeneic ABCB5+ Mesenchymal Stromal Cell Treatment in Recessive Dystrophic Epidermolysis Bullosa // Cells. – 2023. – Vol. 12. – № 11. – P. 1468. DOI 10.3390/cells12111468. PMID: 37296590; PMCID: PMC10252830.
Dieter K., Niebergall-Roth E., Daniele C., Fluhr S., Frank N.Y., Ganss C., Kiritsi D., McGrath J.A., Tolar J., Frank M.H., Kluth M.A. ABCB5+ mesenchymal stromal cells facilitate complete and durable wound closure in recessive dystrophic epidermolysis bullosa // Cytotherapy. – 2023. – Vol. 25. – № 7. – P. 782-788. DOI 10.1016/j.jcyt.2023.01.015. PMID: 36868990; PMCID: PMC10257763.
Bonafont J., Mencía A., Chacón-Solano E., Srifa W., Vaidyanathan S., Romano R., Garcia M., Hervás-Salcedo R., Ugalde L., Duarte B., Porteus M.H., Del Rio M., Larcher F., Murillas R. Correction of recessive dystrophic epidermolysis bullosa by homology-directed repair-mediated genome editing // Mol Ther. – 2021. – Vol. 29. – № 6. – P. 2008-2018. DOI 10.1016/j.ymthe.2021.02.019. PMID: 33609734; PMCID: PMC8178438.
Rashidghamat E., Kadiyirire T., Ayis S., Petrof G., Liu L., Pullabhatla V., Ainali C., Guy A., Aristodemou S., McMillan J.R., Ozoemena L., Mee J., Pramanik R., Saxena A., Nuamah R., de Rinaldis E., Serrano S., Maurin C., Martinez-Queipo M., Lwin S.M., Ilic D., Martinez A., Dazzi F., Slaper-Cortenbach I., Westinga K., Zeddies S., van den Broek M., Onoufriadis A., Mellerio J.E., McGrath J.A. Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa // J Am Acad Dermatol. – 2020. – Vol. 83. – № 2. – P. 447-454. DOI 10.1016/j.jaad.2019.11.038. PMID: 31786163.
Kühl T., Mezger M., Hausser I., Handgretinger R., Bruckner-Tuderman L., Nyström A. High Local Concentrations of Intradermal MSCs Restore Skin Integrity and Facilitate Wound Healing in Dystrophic Epidermolysis Bullosa // Mol Ther. – 2015. – Vol. 23. – № 8. – P. 1368-1379. DOI 10.1038/mt.2015.58. PMID: 25858020; PMCID: PMC4817872.
Alexeev V., Donahue A., Uitto J., Igoucheva O. Analysis of chemotactic molecules in bone marrow-derived mesenchymal stem cells and the skin: Ccl27-Ccr10 axis as a basis for targeting to cutaneous tissues // Cytotherapy. – 2013. – Vol. 15. – № 2. – P. 171-184.e1. DOI 10.1016/j.jcyt.2012.11.006. PMID: 23321329; PMCID: PMC3551218.
Alexeev V., Uitto J., Igoucheva O. Gene expression signatures of mouse bone marrow-derived mesenchymal stem cells in the cutaneous environment and therapeutic implications for blistering skin disorder // Cytotherapy. – 2011. – Vol. 13. – № 1. – P. 30-45. DOI 10.3109/14653249.2010.518609. PMID: 20854215.